AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03699436 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electrotherapy with Galvanic Current
Description: The experimental group will receive an electrotherapy treatment with galvanic current in their hands.This protocol will be administered at weekly sessions of 30 minutes with a period of 3 times / week with a total of 20 sessions, distributed over a 7-week period. They will be evaluated at baseline, after the end of the last treatment session and after two months of follow-up.
Study NCT03699436 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control without Electric Stimulation Therapy
Description: The control group continue with their usual conservative and pharmacological treatment and will not receive electrotherapy treatment. They will be evaluated too at baseline, after the end of the last treatment session and after two months of follow-up.
Study NCT04856644 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4-month rifapentine-based regimen
Description: 8 weeks of isoniazid, pyrazinamide, rifapentine, and moxifloxacin, followed by 9 weeks of isoniazid, rifapentine and moxifloxacin
Study NCT04660630 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Gene detection of therapeutic drugs for chronic cardiovascular and cerebrovascular diseases
Description: According to the results of drug gene chip detection, we combined with the clinical characteristics of the patient to choose more suitable cardiovascular and cerebrovascular treatment drugs.
Study NCT04660630 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Regular follow-up and patient education
Description: The subjects received regular follow-up and patient education.
Study NCT04660630 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Regular follow-up and patient education
Description: The subjects received regular follow-up and patient education.
Study NCT00044915 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Repinotan HCl (BAYX3702)
Description: All patients receive 1.25 mg of repinotan
Study NCT00044915 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: All patients receive 1.25 mg of placebo
Study NCT00657059 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: irbesartan
Description: In the ARB lead-in phase, each subject will be on a strict sodium-restricted diet ( \< 5 g NaCl/day), and then given a stable dose (150mg \~ 300mg/day) of irbesartan (Aprovel) for 3 months until reaching the target blood pressure (BP) level of ≤ 125/75 mmHg. Patients will continue ARB treatment in the drug treatment phase and at lease 3 years in the follow-up phase.
Study NCT00657059 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methylprednisolone (MP) or prednisone (pred)
Description: Patients will take oral Pred ( 0.5 mg/kg/d) on alternate days, and on the first, third and fifth months of the drug treatment phase, patients will be given intravenous pulse therapy with methylprednisolone ( 0.5 g/day) for 3 successive days. And after 6 months, Pred should be tapered to be stopped until the end of the 12-month course of treatment.
Study NCT00657059 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mycophenolate mofetil (MMF)
Description: Patients will take MMF 1.0g bid (wt ≥ 50kg) or 0.75g bid (wt \< 50kg) for the first 6-month of drug treatment phase, then to 0.5 bid (wt ≥ 50kg) for the remaining 6-month.
Study NCT02714725 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: During bypass, patients will receive dexmedetomidine infusion 0.5 mcg/kg/hr
Study NCT02714725 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for Dexmedetomidine normal saline infusion
Description: During bypass, patients will receive normal saline infusion
Study NCT02714725 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Propofol infusion
Description: During bypass, patients will receive propofol infusion 50 - 70 mcg/kg/min
Study NCT02714725 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol infusion
Description: During bypass, patients will receive propofol infusion 50 - 70 mcg/kg/min
Study NCT01486953 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desflurane
Description: Using random numbers, patients were divided into two groups to receive either sevoflurane or desflurane. After induction of anesthesia and intubation, the patient's lungs were ventilated in constant-flow VCV mode by an anesthetic Ventilator (Datex-Ohmeda, GE healthcare, Finland). Ventilator settings were tidal volume 10 ml/kg, inspiratory:expiratory (I:E) ratio 1:1.5, inspired oxygen concentration (FiO2) 0.5 with air, and 3 L/min of inspiratory fresh gas flow. End-inspiratory pause was set 20% of total breathing cycle. Positive end-expiratory pressure (PEEP) was not used. Respiratory rate was adjusted to maintain an end-tidal CO2 pressure of 33-35 mmHg. Patients received desflurane 6-7% for maintenance of anesthesia.
Study NCT01486953 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane
Description: Using random numbers, patients were divided into two groups to receive either sevoflurane or desflurane. After induction of anesthesia and intubation, the patient's lungs were ventilated in constant-flow VCV mode by an anesthetic Ventilator (Datex-Ohmeda, GE healthcare, Finland). Ventilator settings were tidal volume 10 ml/kg, inspiratory:expiratory (I:E) ratio 1:1.5, inspired oxygen concentration (FiO2) 0.5 with air, and 3 L/min of inspiratory fresh gas flow. End-inspiratory pause was set 20% of total breathing cycle. Positive end-expiratory pressure (PEEP) was not used. Respiratory rate was adjusted to maintain an end-tidal CO2 pressure of 33-35 mmHg. Patients received sevoflurane 2-2.5% for maintenance of anesthesia.
Study NCT03891303 — intervention group
Intervention type: OTHER
Intervention: Allogenic blood transfusion (ABT)
Description: During elective open aortic surgery, the autologous blood from ICS was processed and re-transfused in all patients. However, TR group additionally received ABT.
Study NCT00699452 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: candesartan
Description: Candesartan 8 mg/d for two weeks, then 16 mg/d until valve replacement surgery (approximately 3 months)
Study NCT00699452 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study NCT04385888 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low-calorie sweetener restriction
Description: Participants will avoid low-calorie sweetened beverages and other sources of low-calorie sweeteners for 12 weeks and will instead consume unsweetened alternatives, such as still or sparkling water
Study NCT01557283 — intervention group
Intervention type: OTHER
Intervention: Enbrel treatment
Description: Enbrel SC 50mg once weekly or 25mg twice weekly
Study NCT02730988 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weight Stable Group
Description: The weight stable control group is monitored bi-weekly by study staff to ensure weight stability over the course of the study. During group sessions, participants are weighed and encouraged to maintain weight within ±5% of baseline. They also receive non-weight loss health related topics presented by study staff. If participants attend 75% of the educational sessions, all baseline and follow-up testing sessions, and maintain weight stability over the course of the study (defined as less than a 5% differential between weight measured at week 0 and 24), they will be eligible to receive up to 3 months of Medifast MRPs along with a 30-60 minute RD-led dietary instruction session on how to follow the Medifast 4 \& 2 \& 1 Plan.
Study NCT02730988 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Weight Stable Group
Description: The weight stable control group is monitored bi-weekly by study staff to ensure weight stability over the course of the study. During group sessions, participants are weighed and encouraged to maintain weight within ±5% of baseline. They also receive non-weight loss health related topics presented by study staff. If participants attend 75% of the educational sessions, all baseline and follow-up testing sessions, and maintain weight stability over the course of the study (defined as less than a 5% differential between weight measured at week 0 and 24), they will be eligible to receive up to 3 months of Medifast MRPs along with a 30-60 minute RD-led dietary instruction session on how to follow the Medifast 4 \& 2 \& 1 Plan.
Study NCT00861263 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: overtube use during enteroscopy
Description: use of overtube for the regular scheduled enteroscopy
Study NCT01377077 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: punchgrafting
Description: autologous skin transplantation of small skinbiopsies taken from the hip and replaced in the depigmented lesions
Study NCT01377077 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: punchgrafting
Description: autologous skin transplantation of small skinbiopsies taken from the hip and replaced in the depigmented lesions
Study NCT01377077 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: punchgrafting
Description: autologous skingrafting of small skin biopsies taken from the hip en placed in the depigmented lesions
Study NCT01377077 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: punchgrafting
Description: autologous skingrafting of small skin biopsies taken from the hip en placed in the depigmented lesions
Study NCT05031169 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: interdental papilla surgical reconstructiion
Description: Surgical treatment of receding interdentalpapillae
Study NCT05031169 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: interdental papilla surgical reconstructiion
Description: Surgical treatment of receding interdentalpapillae
Study NCT00519961 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Elecsys®proBNP
Study NCT01616433 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: AFEP
Description: Arthritis Foundation Exercise Program (10 weeks, twice a week, 60 minutes per session)
Study NCT01616433 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 10 Keys to Healthy Aging
Description: 10 Keys to Healthy Aging. 10 week program, twice a week, 75 minutes per session.
Study NCT03527914 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Goal Based Outcomes
Description: Up to three goals can be tracked during treatment, although patients often decide to just focus on one. Progress on the goal is then quantitatively rated by the patient, with the provider, at every appointment. Adjustments in the care are then made in an iterative process to ensure that the goal will be met.
Study NCT03527914 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual
Description: Patients will receive their standard care at the Outpatient Mental Health Service
Study NCT02579707 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AG120
Description: AG120 in fed and fasted conditions. Part 2- AG120 single dose exposure
Study NCT02579707 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AG120
Description: AG120 in fed and fasted conditions. Part 2- AG120 single dose exposure
Study NCT00036686 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Soy protein isolate
Description: Arm I: Patients receive oral soy protein isolate twice daily and oral multivitamins once daily.
Study NCT00036686 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Arm II: Patients receive oral placebo twice daily and oral multivitamins once daily.
Study NCT01099423 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: timing of surgery
Study NCT01099423 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: gene expression analysis
Study NCT01099423 — intervention group
Intervention type: GENETIC
Group type: ACTIVE_COMPARATOR
Intervention: gene expression analysis
Study NCT01099423 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: biologic sample preservation procedure
Study NCT01099423 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: biologic sample preservation procedure
Study NCT01099423 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Study NCT01099423 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: laboratory biomarker analysis
Study NCT01099423 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: therapeutic conventional surgery
Study NCT01499355 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: mycophenolate mofetil
Description: titrated to a target daily dose of 2 g (1 g twice daily)
Study NCT00514761 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD6244
Description: oral vial
Study NCT00514761 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: oral tablet
Study NCT01569165 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cleansing teeth after topical fluoride therapy
Description: washing with water 0, 15 or 30 min after APF treatment or cleansing teeth with cotton roll immediately following APF treatment.
Study NCT02685670 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anti-CD19 CAR-T
Description: Ex vivo-expanded autologous T cells modified to express CD19 CAR
Study NCT02685670 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Study NCT02685670 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Study NCT01209845 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ketamine
Description: intravenous ketamine(0.2 mg/kg) over 1-2 minutes IV
Study NCT04350216 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sarilumab 200 MG/1.14 ML Subcutaneous Solution [KEVZARA]
Description: The treatment of sarilumab 200mg will be administered every two weeks subcutaneously.~Each patient will be followed for 6 months from the start of treatment. The last administration of Sarilumab will be 2 weeks before the end of the study.
Study NCT04549337 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise training
Description: Feasibility and safety of 3 different training protocols will be tested. Therefore the intervention is three different exercise protocols (4X4, 6X1, and 10-20-30). The exercise workload is set according to the patients HRmax or wattmax from a VO2max test at the baseline testing. All training protocols have a duration of 38 minutes and start with a 10-minute warm up and a 3-7-minute cool-down period. The intervals in the training protocols are interspersed with a 3-minute active rest. Therefore the three exercise protocols are matched on duration, and they all fall within the category of high-intensity-interval training.~The accumulated time spend with a heart rate >85% of HR max will be evaluated to determine the intensity.
Study NCT04549337 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise training
Description: Feasibility and safety of 3 different training protocols will be tested. Therefore the intervention is three different exercise protocols (4X4, 6X1, and 10-20-30). The exercise workload is set according to the patients HRmax or wattmax from a VO2max test at the baseline testing. All training protocols have a duration of 38 minutes and start with a 10-minute warm up and a 3-7-minute cool-down period. The intervals in the training protocols are interspersed with a 3-minute active rest. Therefore the three exercise protocols are matched on duration, and they all fall within the category of high-intensity-interval training.~The accumulated time spend with a heart rate >85% of HR max will be evaluated to determine the intensity.
Study NCT04548414 — intervention group
Intervention type: OTHER
Intervention: No.
Description: This is an observational study with no intervention.
Study NCT00142051 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nitric oxide
Description: 80 ppm 8 hrs, 40 ppm 8 hrs, 20 ppm 4 hrs, 10 ppm 4 hrs
Study NCT00142051 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: oxygen
Description: oxygen fi02 21% (room air)
Study NCT02570893 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Adjuvant radiotherapy
Description: Adjuvant radiotherapy (50.4gray/28fraction) followed by 4 cycles of chemotherapy (Paclitaxel and carboplatin) after radical esophagectomy.
Study NCT02570893 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Adjuvant radiotherapy
Description: adjuvant radiotherapy (50.4gray/28fraction) only after radical esophagectomy.
Study NCT02570893 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel and carboplatin
Study NCT03473704 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treatment group (TG)
Description: The Treatment group (TG) will receive the web treatment, which consists of 9 weekly sessions.
Study NCT03473704 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control group (CG)
Description: For ethical reasons, the CG will receive the web treatment once the TG intervention has been completed (as long as it continues to meet the conditions of the study).
Study NCT03638934 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Videos about ACP
Description: Three videos about advanced care planning are provided for self-education.
Study NCT03638934 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Brochure about Life-Sustaining Treatment Act
Description: Brochure about Life-Sustaining Treatment Act are provided for self-education.
Study NCT02047643 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Computer algorithm to initiate pump suspension
Description: If the computer algorithm senses impending risk for hypoglycemia it sends an alert to an on-site physician to recommend a manual suspension of the subject's insulin pump
Study NCT04629001 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Covid-19 PCR , IGM
Description: test for Covid-19
Study NCT01669304 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Verapamil
Study NCT01669304 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sertraline
Study NCT03533621 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic - VSL#3
Description: Subjects received a weekly supply of pills for 12 weeks along with support to change their diet to consume more fruits and vegetables. Subjects met with an interventionist weekly to report on pill consumption, stool changes, and get help with changing their dietary behaviors
Study NCT03533621 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo pill - soy protein powder
Description: Subjects received a weekly supply of pills for 12 weeks along with support to change their diet to consume more fruits and vegetables. Subjects met with an interventionist weekly to report on pill consumption, stool changes, and get help with changing their dietary behaviors
Study NCT03249025 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: Initial dose of 5.0 mg/kg (based on actual weight, up to maximum dose 600 mg) over 45-60 minutes, followed by increases of 0.5 mg/kg each infusion based on tolerability of side effects, to a maximum total dose of 600 mg. The initial and subsequent dose may be increased or decreased by 20% based on patient comorbidities, age and previous experience
Study NCT03249025 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: initial dose of 0.25 mg/kg (based on actual weight) over 45-60 minutes (rounded to nearest 5 mg), increased by 10mg each infusion based on tolerability of side effects. The initial and subsequent dose may be increased or decreased by 20% based on patient comorbidities, age and previous experience
Study NCT04592861 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: carbon ion RT
Description: daily carbon ion radiotherapy
Study NCT04592861 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy drug
Description: Subjects who receive carbon ion radiotherapy may receive additional chemotherapy afterwards, at the discretion of the treating physicians. Subjects on the control arm are also expected to receive chemotherapy, using a regimen selected by the treating physicians.
Study NCT04592861 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy drug
Description: Subjects who receive carbon ion radiotherapy may receive additional chemotherapy afterwards, at the discretion of the treating physicians. Subjects on the control arm are also expected to receive chemotherapy, using a regimen selected by the treating physicians.
Study NCT00827801 — intervention group
Intervention type: BEHAVIORAL
Intervention: MDASI-HF Questionnaire
Description: M. D. Anderson Symptom Inventory - Heart Failure (MDASI-HF) questionnaire rating symptoms given in clinic Day 1, Weeks 4 \& 8.
Study NCT04142450 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CoolSculpting® System
Description: Each participant underwent a single treatment session that was comprised of timed segments of cooling followed by 2 minutes of manual massage.
Study NCT00389857 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza Virus Vaccine (Fluzone®)
Description: 0.25 mL, Intramuscular (infant/children dose)
Study NCT03436706 — intervention group
Intervention type: OTHER
Intervention: exposure
Description: exposure to chronic stress
Study NCT01810692 — intervention group
Intervention type: DEVICE
Intervention: Group1:Spiriva® Respimat®
Description: COPD patients using Respimat®
Study NCT01810692 — intervention group
Intervention type: DEVICE
Intervention: Group2:Hirobriz®/Oslif®/Onbrez® Breezhaler®
Description: COPD patients using Breezhaler®®